Hoth Therapeutics (HOTH)
(Delayed Data from NSDQ)
$1.06 USD
-0.20 (-15.87%)
Updated Sep 6, 2024 04:00 PM ET
Pre-Market: $0.97 -0.09 (-8.49%) 8:42 AM ET
2-Buy of 5 2
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Hoth Therapeutics, Inc. [HOTH]
Reports for Purchase
Showing records 1 - 17 ( 17 total )
Company: Hoth Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HT-ALZ Manufacturing Partnership Established; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Hoth Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Cancer Clinical Trial Expansion; Pipeline Initiatives; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Hoth Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical HT-ALZ Data Presented; Equity Financing Complete; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Hoth Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Solving Skin Toxicities of Popular Cancer Drugs; Initiate at Buy and $4 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Hoth Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We are terminating coverage of Hoth Therapeutics, Inc. due to termination of research services.
Provider: Diamond Equity Research LLC
Analyst: Research Department
Company: Hoth Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Targeting Promising Market with Encouraging Early-Stage Data for Potential Alzheimer''s Disease Therapeutic
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: Hoth Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Upcoming Clinical Milestones Supported by Strong Balance Sheet
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: Hoth Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Hoth Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Quarterly Results as Expected, With Numerous Upcoming Milestones
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: Hoth Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Numerous Positive Recent Developments with Strengthened Balance Sheet to Execute
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: Hoth Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Hoth Therapeutics is targeting numerous large addressable markets.-Reinstating Coverage
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: Hoth Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We are terminating coverage due to termination of research services.
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: Hoth Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Animal Trials Commence to Assess Potential Efficacy of Vaccine HaloVax
Provider: DIAMOND EQUITY RESEARCH LLC
Analyst: DIAMOND H
Company: Hoth Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Hoth Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Numerous Positive Developments for HOTH in Challenging Macro Environment
Provider: DIAMOND EQUITY RESEARCH LLC
Analyst: DIAMOND H
Company: Hoth Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Increasing Research Efforts with Numerous Early Stage Initiatives
Provider: DIAMOND EQUITY RESEARCH LLC
Analyst: DIAMOND H
Company: Hoth Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
|